Altria Raised Guidance and Then Refused to Say Why
The biggest swing factor in smokeable profit vanished from the prepared remarks — and management declined three separate times to size it.
MO · Earnings Call · 2026-10-29
The raise nobody will size
Altria lifted full-year adjusted diluted EPS guidance to $5.66–$5.74, a 4.5%–6% growth rate off a $5.42 base, up from the 2.5%–5% range it opened the year with. Third-quarter adjusted EPS rose 4.8%; the nine-month figure rose 5.1%. On the surface this is a well-executed quarter from a $128 billion tobacco company yielding about 5.9%. But the raise has a hole in it. The single largest swing factor in smokeable profitability — the double-duty drawback on import-export activity — does not appear once in the prepared remarks. It was a top-ranked keyword a year ago (Duty drawback, 2025Q4), and in April Sal Mancuso told investors plainly: “You will see increases in the export volume and the benefit of the duty drawback as the year progresses.” — Salvatore Mancuso, Chief Financial Officer (CFO) · 2026-04-30 This quarter he would not put a number on next year. Three analysts tried. Pallav Mittal asked whether the ~$500 million annualized run-rate could compound to $1 billion. The answer:Note the tell: the PMI contract manufacturing agreement does not begin until 2027, so next year's benefit is structurally larger than the current run-rate — and management still will not frame the shape. Pressed on flat ex-drawback cigarette EBIT, Mancuso pushed back: “I think it's, frankly, a little unfair to pick out one aspect of the margin and pull it out and say, 'Well, EBIT is flat.'” — Salvatore Mancuso, Chief Executive Officer · 2026-10-29 Fair enough. But it is also the aspect with the most leverage on 2027, and it has moved from the script to the defensive crouch.No, we're not providing that range. I understand the question. I'll remind you... you are not seeing the impact of the contract manufacturing agreement with PMI, yet that will happen next year.
Cowboy Cut is a pricing story in a value costume
Marlboro's share of the premium segment reached 60%, up 0.3 year-over-year and 0.4 sequentially, while total PM USA retail share expanded 0.2 points sequentially. The mechanism is Cowboy Cut: roughly 100,000 stores, about 75% of cigarette volume, and — critically — a stated intent to raise price on it. Management explicitly cites Marlboro Special Select and Marlboro Black as precedent for "introductory pricing" followed by PM USA "taking pricing or margin up those SKUs over time." Faham Baig's observation that Cowboy Cut now sells above Marlboro Black in some states is the whole revenue-growth-management machine in miniature. In July, this was framed modestly: “You should think of Cowboy Cut as one of the many tools in the suite of RGM tools that PM USA uses to engage with consumers.” — Salvatore Mancuso, Chief Executive Officer (CEO) · 2026-07-30 It is no longer one tool among many; it is the load-bearing one. That is the portfolio approach doing real work — discount share at 34.1% of the category, up 2 points, with Basic up 1.8 points year-over-year — without surrendering the premium segment. Cigarette volumes fell 4% inventory-adjusted versus an estimated 5% industry decline. The flywheel is holding.on! PLUS: shipments up 13%, scanner down mid-teens
This is the quarter's messiest disclosure. on! reported shipment volume rose 13.3% to 47.8 million cans, yet scanner data points the other way. “When I look at scanner data, it is down mid-teens or something like that. So is there a significant inventory as you roll out the 12 mg?” — Pallav Mittal, Analyst · 2026-10-29 Mancuso's answer leaned on pipeline: “I wouldn't say significant, but I would say there's obviously some pipeline inventory as we launched the 12-milligram...” — Salvatore Mancuso, Chief Executive Officer · 2026-10-29 plus pouches-versus-cans measurement noise. What is not noise: on! retail share was 8.3%, up only 0.1 year-over-year and down 0.3 sequentially — a second consecutive quarter of sequential slippage in a category that added 5.8 share points and now exceeds 60% of the total oral category. The response is flavor and strength: Blueberry Mint, Mango Pineapple, and Watermelon Mint arriving in select stores in November. Those SKU-level names are pure company-unique vocabulary — no other reporter in the last five days used them, and Japan Tobacco's RRP volume language shares nothing with Altria's set. Long-term conviction remains: “we believe over the long term, tobacco-like margins are very achievable in this category.” — Salvatore Mancuso, Chief Executive Officer · 2026-10-29 The catch is that with the category leader cutting price per pouch, the debate is about margin, and Altria keeps answering with volume.Suing your own regulator is genuinely new
During the quarter Helix and NJOY filed suit against the FDA, asking a court to enforce the 180-day statutory review clock and let applications pending beyond it stay in market. Compare the language from twelve months ago:From "collaborative" to litigation in four quarters is a real strategic pivot, and it is the origin of the efficient authorization process theme now near the top of Altria's own keyword stack. The FDA's announcement that it will revisit the 2021 PMTA rule is a partial concession. NJOY ACE, by contrast, is a four-quarter no-news item: this quarter, “We have not announced when we're going back in the market, but we do plan on being back in the e-vapor market.” — Salvatore Mancuso, Chief Executive Officer · 2026-10-29 In July it was: “We have not announced the timing of when we plan to re-enter the category, but we do plan on re-entering that category.” — Salvatore Mancuso, Chief Executive Officer (CEO) · 2026-07-30 Near verbatim. That is not a pipeline; that is a holding pattern.It's been a very collaborative process with constant engagement through the application review process, which is very different and very encouraging from the FDA we experienced under the previous administration.